|
|
|
| Role of tirofiban combined with anisodamine injection in protecting myocardial function recovery and endothelial function in patients with STEMI after PCI |
| ZHANG Xiaojing1, LIU Huiliang1, ZHU Lin1, ZHANG Jiao2, YU Hong2, LI Yi1 |
1. Institute of Cardiology, the Third Medical Center, General Hospital of Chinese PLA,Beijing 100039,China;
2. Department of Cardiology, Beijing Electric Power Hospital, State Grid Corporation of China,Beijing 100073,China |
|
|
|
|
Abstract ObjectiveTo investigate the protective role of tirofiban combined with anisodamine injection in myocardial function recovery and endothelial function in patients with STEMI after PCI.Methods One hundred and sixteen cases of STEMI patients treated in our hospital between July 2016 and February 2018 were selected as the subjects. Using the simple random method, the patients were divided into the control group and the observation group. Both groups were treated with PCI, but the control group was given tirofiban, while the observation group received tirofiban + anisodamine. The changes of myocardial reperfusion, cardiac function, vascular endothelial injury markers and adverse cardiovascular events were compared between the two groups before and after treatment.Results The 2 h ST segment drop rate, cTFC and the myocardial perfusion grade of the observation group were better than those of the control group (P<0.05). The left ventricular end-diastolic diameter (LVEDD), left ventricular ejection force (LVEF) and left ventricular end-diastolic diameter (LVEDD) were improved after operation in both groups (P<0.05). At T1 and T2, the LVEDD and LVEF of the observation group were better than those of the control group (P<0.05). After treatment, the levels of vascular endothelial growth factor and ET-1 in the two groups were lower, but the levels of NO were higher (P<0.05). After treatment, the levels of vascular endothelial growth factor and ET-1 in the observation group were lower than those in the control group(荒唐的表达). The incidence of adverse cardiovascular events within 6 months after PCI was 17.24% (10/58) in the observation group and 3.45% (2/58) in the control group.Conclusions Tirofiban combined with anisodamine injection can boost myocardial perfusion in patients with STEMI, improve cardiac function, protect vascular endothelium and reduce the risk of adverse cardiovascular events.
|
|
Received: 25 November 2019
|
|
|
|
|
|
| [1] |
饶萌萌, 赵 蓓, 王守力. 急性ST段抬高型心肌梗死冠状动脉血栓研究现状[J]. 医学综述, 2017, 23(5):847-851.
|
| [2] |
王 莉, 谷臣锋, 刘剑雄. 介入术中高血栓负荷ST段抬高型心肌梗死患者处理策略研究进展[J]. 心血管病学进展, 2017, 38(3):330-334.
|
| [3] |
李婷婷, 郝应禄, 李燕萍. 急性ST段抬高型心肌梗死溶栓中抗凝治疗进展[J]. 中国医师进修杂志, 2016, 39(2):182-185.
|
| [4] |
杜 蕊, 张冬梅, 李 颖, 等. 替罗非班对急性ST段抬高型心肌梗死介入治疗的临床研究[J]. 中国临床药理学杂志, 2016, 32(13):1162-1165.
|
| [5] |
崔广凯. 预防性冠脉内应用山莨菪碱对STEMI患者直接PCI术后心功能的影响[J]. 中西医结合心血管病杂志:电子版, 2016, 4(19):64-65.
|
| [6] |
中华医学会心血管病学分会. 急性ST段抬高型心肌梗死诊断和治疗指南[J]. 中华心血管病杂志, 2015, 43(5):675-690.
|
| [7] |
周玉杰. 冠心病规范化治疗[M]. 北京:北京大学医学出版社, 2009.
|
| [8] |
韦吉伟. 急性心肌梗死的治疗进展[J]. 临床合理用药杂志, 2017, 10(5):180-181.
|
| [9] |
Yin W H , Lu T H , Chen K C , et al. The temporal trends of incidence, treatment, and in-hospital mortality of acute myocardial infarction over 15 years in a Taiwanese population[J]. Int J Cardiol, 2016, 209(7):103-113.
|
| [10] |
Spath N B , Mills N L , Cruden N L . Novel cardioprotective and regenerative therapies in acute myocardial infarction: a review of recent and ongoing clinical trials[J]. Future Cardiol, 2016, 12(6):655-672.
|
| [11] |
He B , Ding S , Qiao Z , et al. Influence of microvascular dysfunction on regional myocardial deformation post-acute myocardial infarction: insights from a novel angiographic index for assessing myocardial tissue-level reperfusion[J]. Int J Cardiovasc Imaging, 2016, 32(5):711-719.
|
| [12] |
Poupko J M, Baskin S I, Moore E. The pharmacological properties of anisodamine[J]. J Appl Toxicol, 2007, 27(2):116-121.
|
| [13] |
孙 凯, 杨丽敏. 山莨菪碱的药理和临床研究进展[J]. 世界临床药物, 2010, 31(3):182-186.
|
| [14] |
牛红霞, 傅向华. 冠脉内注射山莨菪碱冠状动脉对无复流现象的影响研究[J]. 中国实验诊断学, 2010, 14(10):1579-1582.
|
| [15] |
Lee M J, Han S H, Lee J E, et al. Endothelial dysfunction is associated with major adverse cardiovascular events in peritoneal dialysis patients[J]. Medicine, 2014, 93(11):e73.
|
| [16] |
Hamid M A,Bakhoum S W, Sharaf Y, et al. Circulating endothelial cells and endothelial function predict major adverse cardiac events and early adverse left ventricular remodeling in patients with ST-segment elevation myocardial infarction[J]. J Interv Cardiol, 2016, 29(1):10.
|
| [17] |
马跃东, 李德华. VEGF在心血管疾病治疗中作用的研究进展[J]. 中国老年学杂志, 2011, 31(9):1703-1705.
|
| [18] |
Ataga K I, Derebail V K, Caughey M, et al. Albuminuria is associated with endothelial dysfunction and elevated plasma endothelin-1 in sickle cell anemia [J]. Plos One, 2016, 11(9):e0162652.
|
| [19] |
Talukder M A H, Johnson W M, Varadharaj S, et al. Chronic cigarette smoking causes hypertension, increased oxidative stress, impaired NO bioavailability, endothelial dysfunction, and cardiac remodeling in mice[J]. Am J Physiol Heart Circ Physiol, 2011, 300(1):H388-H396.
|
| [20] |
杨聪德, 刘甲兴, 洪华山. 山莨菪碱及与替罗非班联合辅助治疗急性心肌梗死的效果分析[J]. 中国心血管病研究, 2016, 14(9):834-837.
|
|
|
|
2020, Vol. 31 
